Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium

Figures & data

Table 1 Characteristics of patients at inclusion

Group	A	B
Gender	22 males, 15 females	23 males, 14 females
Mean age (range)	71.7 years (55–85)	72.1 years (56–88)
Mean duration of COPD	13.8 years	12.3 years
Active smoking history	29/37	31/37
Use of IC	30/37	27/37
Use of LABA	20/37	23/37
Mean FEV1 (mL)	1191 ± 185	1249 ± 373
Mean FVC (mL)	2212 ± 803	2433 ± 649

Abbreviations: IC, inhaled corticosteroids; LABA, long-acting beta2-agonists.

Table 2 Changes in respiratory parameters after treatment with tiotropium

Group	A	B
Baseline mean FEV1 (mL)	1191 ± 185	1249 ± 373
Mean FEV1 after tiotropium	1236 ± 201	1423 ± 411
Baseline mean FVC (mL)	2212 ± 803	2433 ± 649
Mean FVC after tiotropium	2284 ± 780	2587 ± 671
Baseline FEF25–75 (mL)	624 ± 418	865 ± 372
FEF25–75 after tiotropium	892 ± 497	1012 ± 438